

A Multicenter Phase 3 Trial of Lobeline Sulfate for Smoking Cessation

Elbert D. Glover, PhD, FAAHB, FASHA; Jessica M. Rath, PhD, MPH, CHES; Eva Sharma, MPH; Penny N. Glover, MEd, CCRC; Molly Laflin, PhD; Philip Tonnesen, MD, PhD; Lawrence Repsher, MD; John Quiring, PhD

Objective: To evaluate the safety and efficacy of sublingual lobeline sulfate for smoking cessation. **Methods:** A multicenter (3 sites), double-blind, parallel, placebo-controlled, phase 3 smoking cessation trial of sublingual formulation of lobeline sulfate. A total of 750 smokers (250 per site) were randomized to either treatment (lobeline sulfate) or placebo with individual smoking ces-

sation counseling lasting up to approximately 10 minutes. **Results:** Efficacy revealed no statistical significance ($P=0.62$) for lobeline sulfate as a smoking cessation aid. **Conclusion:** Sublingual formulation of lobeline sulfate does not appear to be an effective smoking cessation aid.

Key words: lobeline sulfate, smoking cessation, clinical trials
Am J Health Behav. 2010;34(1):101-109
